RT Journal Article
SR Electronic
T1 Highland of COVID-19 outside Hubei: epidemic characteristics, control and projections of Wenzhou, China
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.02.25.20024398
DO 10.1101/2020.02.25.20024398
A1 Xu, Liangde
A1 Yuan, Jian
A1 Zhang, Yaru
A1 Zhang, Guosi
A1 Lu, Fan
A1 Su, Jianzhong
A1 Qu, Jia
YR 2020
UL http://medrxiv.org/content/early/2020/02/29/2020.02.25.20024398.abstract
AB In late December 2019, Chinese authorities reported a cluster of pneumonia cases of unknown aetiology in Wuhan, China1. A novel strain of coronavirus named Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was isolated and identified on 2 January 2020 2. Human-to-human transmission have been confirmed by a study of a family cluster and have occurred in health-care workers 3,4. Until 10 February 2020, 42638 cases of 2019 novel coronavirus disease (COVID-19) have been confirmed in China, of which 31728 came from Hubei Province (Figure). Wenzhou, as a southeast coastal city with the most cases outside Hubei Province, its policy control and epidemic projections have certain references for national and worldwide epidemic prevention and control. We described the epidemiologic characteristics of COVID-19 in Wenzhou and made a transmission model to predict the expected number of cases in the coming days.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the Key Program of National Natural Science Foundation of China (81830027) to J. Qu; the National Natural Science Foundation of China (61871294) to J. Su; the Key Research and Development Program of Zhejiang Province (2020C03036) to L. XuAuthor DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Yeshttps://github.com/ZhangBuDiu/WZ_COVID-19 for R code, case data, and prepared datafiles